Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 26

1.

Loss of PDZK1 expression activates PI3K/AKT signaling via PTEN phosphorylation in gastric cancer.

Zhao C, Tao T, Yang L, Qin Q, Wang Y, Liu H, Song R, Yang X, Wang Q, Gu S, Xiong Y, Zhao D, Wang S, Feng D, Jiang WG, Zhang J, He J.

Cancer Lett. 2019 Jul 1;453:107-121. doi: 10.1016/j.canlet.2019.03.043. Epub 2019 Mar 29.

PMID:
30930234
2.

Retrospective study of the efficacy and toxicity of lobaplatin-etoposide chemotherapy in small cell lung cancer.

Gu L, Zhong D, Yu T, Tang P, Meng F, Qin Q.

Thorac Cancer. 2019 Feb;10(2):226-233. doi: 10.1111/1759-7714.12936. Epub 2019 Jan 2.

3.

NHERF1 inhibits beta-catenin-mediated proliferation of cervical cancer cells through suppression of alpha-actinin-4 expression.

Wang Q, Qin Q, Song R, Zhao C, Liu H, Yang Y, Gu S, Zhou D, He J.

Cell Death Dis. 2018 Jun 4;9(6):668. doi: 10.1038/s41419-018-0711-x.

4.

Comparison of 627 patients with right- and left-sided colon cancer in China: Differences in clinicopathology, recurrence, and survival.

Qin Q, Yang L, Sun YK, Ying JM, Song Y, Zhang W, Wang JW, Zhou AP.

Chronic Dis Transl Med. 2017 Mar 13;3(1):51-59. doi: 10.1016/j.cdtm.2017.02.004. eCollection 2017 Mar 25.

5.

Global Analysis of miRNA-mRNA Interaction Network in Breast Cancer with Brain Metastasis.

Li Z, Peng Z, Gu S, Zheng J, Feng D, Qin Q, He J.

Anticancer Res. 2017 Aug;37(8):4455-4468.

PMID:
28739740
6.

NHERF1 inhibits proliferation of triple-negative breast cancer cells by suppressing GPER signaling.

Wang Y, Peng Z, Meng R, Tao T, Wang Q, Zhao C, Liu H, Song R, Zheng J, Qin Q, He J.

Oncol Rep. 2017 Jul;38(1):221-228. doi: 10.3892/or.2017.5649. Epub 2017 May 18.

PMID:
28535016
7.

NHERF1 Enhances Cisplatin Sensitivity in Human Cervical Cancer Cells.

Tao T, Yang X, Qin Q, Shi W, Wang Q, Yang Y, He J.

Int J Mol Sci. 2017 Jan 12;18(1). pii: E5. doi: 10.3390/ijms18010005.

8.

Osthole inhibits the expressions of collagen I and III through Smad signaling pathway after treatment with TGF-β1 in mouse cardiac fibroblasts.

Liu JC, Wang F, Xie ML, Cheng ZQ, Qin Q, Chen L, Chen R.

Int J Cardiol. 2017 Feb 1;228:388-393. doi: 10.1016/j.ijcard.2016.11.202. Epub 2016 Nov 10.

PMID:
27870967
9.

Hemicelluloses removal in autohydrolysis pretreatment enhances the subsequent alkali impregnation effectiveness of poplar sapwood.

Jiang X, Hou Q, Liu W, Zhang H, Qin Q.

Bioresour Technol. 2016 Dec;222:361-366. doi: 10.1016/j.biortech.2016.10.017. Epub 2016 Oct 8.

PMID:
27741474
10.

NHERF1, a novel GPER associated protein, increases stability and activation of GPER in ER-positive breast cancer.

Meng R, Qin Q, Xiong Y, Wang Y, Zheng J, Zhao Y, Tao T, Wang Q, Liu H, Wang S, Jiang WG, He J.

Oncotarget. 2016 Aug 23;7(34):54983-54997. doi: 10.18632/oncotarget.10713.

11.

[Analysis of the relationship of DNA mismatch repair with clinicopathologic features and prognosis of colon cancer].

Qin Q, Ying J, Lyu N, Guo L, Zhi W, Zhou A, Wang J.

Zhonghua Zhong Liu Za Zhi. 2015 Aug;37(8):591-6. Chinese.

PMID:
26714599
12.

Evaluation of the optimal dosage of S-1 in adjuvant SOX chemotherapy for gastric cancer.

Yang L, Yang Y, Qin Q, Zhou A, Zhao J, Wang J, Shu C, Yuan X, Hu S.

Oncol Lett. 2015 Mar;9(3):1451-1457. Epub 2014 Dec 22.

13.

[Correlations between DNA mismatch repair (MMR) and prognosis and prediction of treatment efficacy in stage II/II colon cancer].

Qin Q, Ying J, Lyu N, Guo L, Zhi W, Zhou A, Wang J.

Zhonghua Zhong Liu Za Zhi. 2014 Nov;36(11):844-8. Chinese.

PMID:
25620482
14.

Design, synthesis, and evaluation of nonretinoid retinol binding protein 4 antagonists for the potential treatment of atrophic age-related macular degeneration and Stargardt disease.

Cioffi CL, Dobri N, Freeman EE, Conlon MP, Chen P, Stafford DG, Schwarz DM, Golden KC, Zhu L, Kitchen DB, Barnes KD, Racz B, Qin Q, Michelotti E, Cywin CL, Martin WH, Pearson PG, Johnson G, Petrukhin K.

J Med Chem. 2014 Sep 25;57(18):7731-57. doi: 10.1021/jm5010013. Epub 2014 Sep 11.

15.

Dose-finding study on adjuvant chemotherapy with S-1 plus oxaliplatin for gastric cancer.

Yang L, Yang Y, Qin Q, Zhou A, Zhao J, Wang J, Shu C, Yuan X, Hu S.

Mol Clin Oncol. 2014 Jan;2(1):93-98. Epub 2013 Sep 23.

16.

Famitinib in metastatic renal cell carcinoma: a single center study.

Zhang W, Zhou AP, Qin Q, Chang CX, Jiang HY, Ma JH, Wang JW.

Chin Med J (Engl). 2013 Nov;126(22):4277-81.

PMID:
24238512
17.

Phase I study of the safety, pharmacokinetics and antitumor activity of famitinib.

Zhou A, Zhang W, Chang C, Chen X, Zhong D, Qin Q, Lou D, Jiang H, Wang J.

Cancer Chemother Pharmacol. 2013 Nov;72(5):1043-53. doi: 10.1007/s00280-013-2282-y. Epub 2013 Sep 17.

PMID:
24043137
18.

A phase II trial of oxaliplatin plus S-1 as a first-line chemotherapy for patients with advanced gastric cancer.

Yang L, Song Y, Zhou AP, Qin Q, Chi Y, Huang J, Wang JW.

Chin Med J (Engl). 2013;126(18):3470-4.

PMID:
24034092
19.

[Analysis of prognostic factors after radical resection in 628 patients with stage II or III colon cancer].

Qin Q, Yang L, Zhou AP, Sun YK, Song Y, DU F, Wang JW.

Zhonghua Zhong Liu Za Zhi. 2013 Mar;35(3):212-6. doi: 10.3760/cma.j.issn.0253-3766.2013.03.011. Chinese.

PMID:
23880003
20.

A1120, a nonretinoid RBP4 antagonist, inhibits formation of cytotoxic bisretinoids in the animal model of enhanced retinal lipofuscinogenesis.

Dobri N, Qin Q, Kong J, Yamamoto K, Liu Z, Moiseyev G, Ma JX, Allikmets R, Sparrow JR, Petrukhin K.

Invest Ophthalmol Vis Sci. 2013 Jan 7;54(1):85-95. doi: 10.1167/iovs.12-10050.

Supplemental Content

Loading ...
Support Center